Skip to main content
Complete Olympic Games coverage at your fingertips
Your inside track on the Olympic Games
Enjoy unlimited digital access
per week for 24 weeks
Complete Olympic Games coverage at your fingertips
Your inside track onthe Olympics Games
per week
for 24 weeks
// //

Medicenna Therapeutics Corp TSX: MDNA-T

Today's Change
Real-Time Last Update TSX Last Sale

Today's Trading

Day Low 2.77
Day High 3.15
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors.


Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio


Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

Strong Buy


A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.


What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.


A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest Press Releases

Medicenna Announces That Initiation of MDNA11 Phase 1/2 Study is on Track; Update to be Provided at the PropThink Digital Conference
- GlobeNewswire - Tue Jul 27, 8:00AM CDT
GlobeNewswire - CMTX
Tue Jul 27, 8:00AM CDT
- Phase 1/2 ABILITY Study is designed to evaluate MDNA11, a potentially best-in-class IL-2 Superkine, in patients with advanced solid tumors
Medicenna's IL-2 Superkine Platform Featured in Peer-Reviewed Publication Demonstrating its Superiority and Ability to Reprogram the Tumor Microenvironment in Pancreatic Cancer
- GlobeNewswire - Wed Jul 14, 8:00AM CDT
GlobeNewswire - CMTX
Wed Jul 14, 8:00AM CDT
-- Preclinical results in a pancreatic cancer model show that MDNA109, delivered by an oncolytic adenovirus, induced superior anti-tumor response with tendency towards complete tumor regression, improved survival, and long-term immune memory effect
Medicenna Announces Submission of Clinical Trial Application in Australia for a Phase 1/2 Study of MDNA11
- GlobeNewswire - Wed Jun 23, 8:00AM CDT
GlobeNewswire - CMTX
Wed Jun 23, 8:00AM CDT
-- Initiation of the ABILITY Study, a first-in-human trial, is expected in the third quarter of 2021
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 2.52 +14.68% increase
on 07/23/21
Period Open:3.64
Price movement based on the high, low and last over the given period.
3.82 -24.35% decrease
on 07/06/21
-0.75 (-20.60%) decrease
since 07/02/21
3-Month 2.52 +14.68% increase
on 07/23/21
Period Open:4.44
Price movement based on the high, low and last over the given period.
4.90 -41.02% decrease
on 05/07/21
-1.55 (-34.91%) decrease
since 05/03/21
52-Week 2.52 +14.68% increase
on 07/23/21
Period Open:4.96
Price movement based on the high, low and last over the given period.
7.02 -58.83% decrease
on 12/29/20
-2.07 (-41.73%) decrease
since 07/31/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies